First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo – promising use of Lytix cancer treatment in patients with early-stage melanoma
Source: Lytix Biopharma AS, November 2024
Oslo, Norway, November 6, 2024 – Lytix Biopharma, a Norwegian immuno-oncology company dedicated to being part of tomorrow’s cancer treatment, announces that the first patient has been treated in a new Phase II trial (NeoLIPA). The study evaluates the effect of Lytix’s lead drug candidate, LTX-315, in early-stage patients diagnosed with melanoma. Melanoma is the most severe type of skin cancer with a rising incidence globally and an estimated global market of USD 11 billion by 2030.
“By expanding our clinical trials to early-stage melanoma patients we are adding to our robust portfolio of clinical studies. Melanoma includes an extensive population of patients, implying a vast commercial potential for Lytix Biopharma. In addition, our treatment may provide several important advantages for this patient population,” says Dr. Øystein Rekdal, CEO of Lytix Biopharma.
The investigator-led trial run by Oslo University Hospital (Radiumhospitalet) will enroll approximately 27 patients. The NeoLIPA trial will be led by Dr. Henrik Jespersen, Head of Melanoma at Oslo University Hospital and interim results from the study are expected in H2 2025.